If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 21 - 30 of 295
A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients with Traumatic Injury and Confirm
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival (TAP Study)
Protocol No
SURG-CSL-BE1116-3006-TAP
Categories
An open-label, controlled, randomized, Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA >= 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase wit
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)
Protocol No
SURG-HANSA-CONFIDES
Categories
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Am
This study is being done to answer the following questions:
- Do people with AL amyloidosis respond better to a consolidation treatment that uses either
one high dose of the drug melphalan plus stem cell transplant or more chemotherapy
alone?
- Which treatment plan gives patients a better quality of life?
To determine which treatment plan works better against AL amyloidosis, the study is set up to find out how good the treatments are at lowering the chance of AL amyloidosis causing problems in major organs of the body. The researchers will compare the results from each treatment group.
- Do people with AL amyloidosis respond better to a consolidation treatment that uses either
one high dose of the drug melphalan plus stem cell transplant or more chemotherapy
alone?
- Which treatment plan gives patients a better quality of life?
To determine which treatment plan works better against AL amyloidosis, the study is set up to find out how good the treatments are at lowering the chance of AL amyloidosis causing problems in major organs of the body. The researchers will compare the results from each treatment group.
Protocol No
SWOG-S2213
Categories
An Open-Label, Phase 2b, Global Multi-Center Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertions and Uncommon/Single or Compound Epidermal G
Study of of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Protocol No
TAIHO-TAS6417-201
Categories
A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor
This phase II trial tests the effectiveness of darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent).
Protocol No
NRG-GY033
Categories
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
This study is for persons with recurrent glioblastoma that has failed to respond to or has come back after standard radiotherapy and Temozolomide treatment. The overall goal of this study is to develop Gallium Maltolate (GaM), an experimental drug, as a new oral treatment for patients with glioblastoma brain tumors whose tumor has relapsed after initial treatment or has progressed despite initial treatment.
Protocol No
IIT-CONNELLY-GBM-GAMAY
Categories
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Protocol No
NRG-GY022
Categories
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Protocol No
SWOG-S1827
Categories
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Protocol No
NRG-CC009
Categories
A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Protocol No
SEAGEN-SGNTUC-028-HER2CLIMB-05
Categories